phone Contact Us

Company Updates

Office Relocation Announcement

Office Relocation Announcement

Hong Kong, 25 March 2026

Opharmic Relocates to New Tsim Sha Tsui Headquarters with Grand Opening Ceremony

Opharmic Technology (HK) Limited is excited to announce its successful relocation to a new headquarters in Tsim Sha Tsui (TST) and the official grand opening of the state-of-the-art facility. This move represents a major milestone in the company’s growth journey, providing expanded space and modern infrastructure to support its accelerating development in non-invasive ultrasound medtech.

The new office is located at East Tsim Sha Tsui, Kowloon, a modern location improving accessibility for collaborators and talent while maintaining Opharmic’s strong ties to Hong Kong’s innovation ecosystem. The grand opening event featured a traditional ribbon-cutting ceremony, a customary roast pig blessing, facility tours, and networking sessions attended by over 60 guests, including partners, investors, friends, and industry stakeholders, perfectly embodied Opharmic’s values of community, gratitude, and forward momentum.

This relocation comes at a pivotal stage in the company’s trajectory. Since its founding as a startup in 2018, Opharmic has expanded from a team of 3 to 20 dedicated professionals. The new TST headquarters offers enhanced laboratories, new collaboration spaces, and operational capacity to support Opharmic’s flagship platforms: MeticTouch® for non-invasive ocular drug delivery, and MeticStim® for targeted cell stimulation with diverse applications.

“As we settle into our new home in Tsim Sha Tsui, we celebrate not just a physical move, but the tremendous progress our team has made over the years,” stated Dr. Langston Suen, CEO of Opharmic Technology. “This upgraded facility will enable us to accelerate preclinical and regulatory work as we prepare for First-in-Human trials for our flagship programme. It is a symbol of our evolution from a startup to a mature medtech leader ready to make a meaningful impact for patients.”

COO Sarah Cheung added, “The new space enhances our ability to collaborate across operations, early technology development, product management and quality, regulatory affairs, business development, and marketing—all of which are critical as we move closer to commercialization.”

The TST headquarters features advanced laboratory spaces, smart office elements, and flexible layouts designed for innovation and team growth. It further demonstrates Opharmic’s commitment to cultivating a vibrant, collaborative workplace in one of Hong Kong’s most dynamic districts.

Looking ahead, the new facility will serve as a strategic hub for R&D, investor relations, and partnerships as Opharmic pursues its 2026 annual theme, “煥新 Glow”—symbolizing renewal, innovation, and fresh energy as the team advances preclinical success toward clinical reality throughout the coming year.

Author

Opharmic Technology